{
    "clinical_study": {
        "@rank": "68703", 
        "acronym": "TF", 
        "arm_group": {
            "arm_group_label": "Study Drug", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is a Phase I, first in human, dose-escalation study of MORAb-066, an\n      investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets\n      TF-expressing malignancies that include breast, pancreatic, colorectal, and non-small-cell\n      lung cancer (NSCLC) (adenocarcinoma).  This open-label study will assess the safety,\n      tolerability, and pharmacokinetics of MORAb-066 administered weekly.  This study will\n      identify the MTD when MORAb-066 is administered IV once weekly on a 28-day cycle."
        }, 
        "brief_title": "Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Pancreatic Cancer", 
            "Colorectal Cancer", 
            "Non-small-cell Lung Cancer", 
            "NSCLC", 
            "Adenocarcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Breast Neoplasms", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Colorectal Neoplasms", 
                "Lung Neoplasms", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Objective\n\n      \u2022 To evaluate the safety and tolerability of weekly intravenous (IV) infusions of MORAb-066.\n\n      Secondary Objectives\n\n        -  To identify the dose-limiting toxicities (DLT) and to determine the maximum tolerated\n           dose (MTD) of MORAb-066.\n\n        -  To characterize the pharmacokinetic (PK) properties of MORAb-066.\n\n        -  To identify, on the basis of safety, PK, and pharmacodynamics (PDx) data, a recommended\n           Phase II dose and schedule for MORAb-066.\n\n        -  To make a preliminary assessment of the antitumor activity of MORAb-066.\n\n        -  T\n\n        -  To detect any antibody response (i.e., human antihuman antibodies [HAHA]) to multiple\n           IV infusions to MORAb-066.\n\n      Exploratory Objectives\n\n        -  To evaluate the presence of tissue factor (TF) substrates such as protease activated\n           receptor 2 when applicable.\n\n        -  To evaluate the archived tumor tissue for TF overexpression by immunohistochemistry.\n\n        -  To evaluate whether there are potential biomarkers that correlate responses to\n           MORAb-066."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must meet the following criteria in order to be included in this clinical\n             trial:\n\n               1. Histologically or cytologically confirmed diagnosis of breast, colorectal,\n                  pancreas, or NSCLC (adenocarcinoma) that is metastatic or unresectable for which\n                  there is no effective therapy.\n\n               2. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n                  (see Appendix A).\n\n               3. Measurable disease according to Response Evaluation Criteria in Solid Tumors\n                  (RECIST) v1.1.\n\n               4. Subject has recovered (to Grade \u2264 1) from all clinically significant toxicities\n                  related to prior antineoplastic therapies with the exception of alopecia and\n                  bone marrow and organ functions (described separately below).\n\n               5. Adequate organ system function \u22642 weeks prior to Day1, defined as follows:\n\n                    -  Absolute neutrophil count (ANC) \u22651.5 x 109/L\n\n                    -  Platelets \u2265100 x 109/L\n\n                    -  Hemoglobin \u22659 g/dL\n\n                    -  Prothrombin time/partial thromboplastin time (PT/PTT) within institutional\n                       limits of normal\n\n                    -  Serum total bilirubin \u22641.5 times the upper limit of normal (ULN)\n\n                    -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u22643.0 x\n                       ULN if no liver involvement or \u22645 x ULN with liver involvement.\n\n                    -  Serum creatinine \u22641.5 x ULN or calculated creatinine clearance \u226550 mL/min\n                       as calculated by the Cockcroft-Gault method, OR 24-hour measured urine\n                       creatinine clearance \u226550 mL/min.\n\n               6. Life expectancy of \u226512 weeks.\n\n               7. Female patients of child-bearing potential (see Appendix C), and all male\n                  patients must consent to use a medically acceptable method of contraception\n                  throughout the study period and for 30 days after their last MORAb-066\n                  administration.  A barrier method of contraception must be included.\n\n               8. Patients must be \u226518 years of age.\n\n               9. Patients entering this study will be asked to provide archival tissue from a\n                  previous tumor biopsy (if available) for correlative testing.  If tissue is not\n                  available, the subject will still be eligible for enrollment into the study.\n\n              10. Ability to understand the nature of this study and give written informed\n                  consent.\n\n        Exclusion Criteria:\n\n          -  Patients who meet any of the following criteria will be excluded from trial entry:\n\n               1. Patients currently receiving cancer therapy (i.e., chemotherapy, radiation\n                  therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor\n                  embolization).\n\n               2. Use of an investigational drug within 21 days or 5 half-lives (whichever is\n                  shorter) prior to the first dose of MORAb-066.  For investigational drugs for\n                  which 5 half-lives is less than 21 days, a minimum of 10 days between\n                  termination of the investigational drug and administration of MORAb-066 is\n                  required.\n\n               3. Any major surgery, chemotherapy, radiotherapy, or immunotherapy within the last\n                  21 days (limited palliative radiation is allowed \u22652 weeks).\n\n               4. Subject has received wide field radiotherapy (including therapeutic\n                  radioisotopes such as strontium 89) \u2264 28 days or limited field radiation for\n                  palliation \u2264 14 days prior to starting study drug or has not recovered from side\n                  effects of such therapy.\n\n               5. Known intracranial involvement, leptomeningeal metastases or spinal cord\n                  compression due to disease.\n\n               6. Known allergy or hypersensitivity to monoclonal antibodies.\n\n               7. Known bleeding diathesis, such as factor deficiency, factor inhibitor, platelet\n                  disorder, or who are on active anticoagulation, or any dose of aspirin within 5\n                  days prior to first dose of MORAb-066.\n\n               8. Known prior significant bleeding history.\n\n               9. Patients with ureteral stents or 3+ blood in the urine at baseline.\n\n              10. Patients who are receiving chronic systemic anticoagulation therapy (warfarin\n                  sodium or heparin, etc.).\n\n              11. Patients who received a previous mAb therapy and have evidence of an immune or\n                  allergic reaction or previously documented HAHA reaction.\n\n              12. A serious non-healing wound, active ulcer, or untreated bone fracture.  An\n                  abdominal fistula or gastrointestinal perforation <6 months prior to treatment.\n\n              13. History of hematemesis or hemoptysis (defined as having bright red blood of 1/2\n                  teaspoon or more per episode) \u22641 month prior to study enrollment.\n\n              14. Subject has cardiac dysfunction including any of the following:\n\n                    -  Myocardial infarction within the last 6 months, documented by persistent\n                       elevated cardiac enzymes or persistent regional wall abnormalities on\n                       assessment of  left ventricular ejection fraction function\n\n                    -  QTcF >470 msec\n\n                    -  History of documented congestive heart failure (New York Heart Association\n                       functional classification III-IV [see Appendix B])\n\n                    -  Angina not well-controlled by medication\n\n              15. A serious active infection (bacterial or fungal) at the time of treatment, or\n                  another serious underlying medical condition that would impair the ability of\n                  the subject to receive protocol treatment.\n\n              16. Chronic inflammatory disorder(e.g., inflammatory bowel disease, active\n                  vasculitis).\n\n              17. Herbal preparations/medications must be discontinued 7 days prior to first dose\n                  of study drug (see Section 5.3.1).\n\n              18. Known diagnosis of human immunodeficiency virus, Hepatitis B or Hepatitis C.\n\n              19. Women who are pregnant or lactating.\n\n              20. Psychological, familial, sociological, or geographical conditions that do not\n                  permit compliance with the protocol.\n\n              21. Concurrent condition that in the investigator's opinion would jeopardize\n                  compliance with the protocol.\n\n              22. Inability or unwillingness to comply with study and/or follow-up procedures\n                  outlined in the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01761240", 
            "org_study_id": "MORAb-066-001"
        }, 
        "intervention": {
            "arm_group_label": "Study Drug", 
            "intervention_name": "MORAb-066", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 29, 2013", 
        "location": [
            {
                "contact": {
                    "email": "ingrid-block@ouhsc.edu", 
                    "last_name": "Ingrid Block", 
                    "phone": "405-271-8777"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "Oklahoma University"
                }, 
                "investigator": {
                    "last_name": "Carla Kurkjian, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Scottina Pickens", 
                    "phone": "615-329-0570"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology"
                }, 
                "investigator": {
                    "last_name": "Johanna Bendell, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of the Safety, Tolerability, and PK of MORAb-066, a Humanized Monoclonal Antibody to Human TF, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or NSCLC (Adenocarcinoma) Malignancies", 
        "overall_official": [
            {
                "affiliation": "SCRI Development Innovations, LLC", 
                "last_name": "Johanna Bendell, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Oklahoma University", 
                "last_name": "Carl Kurkjian, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum Tolerated Dose", 
            "safety_issue": "Yes", 
            "time_frame": "24 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01761240"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Morphotek", 
        "sponsors": {
            "collaborator": {
                "agency": "SCRI Development Innovations, LLC", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Morphotek", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}